(Favezelimab + pembrolizumab) by Merck for Bladder Cancer: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Favezelimab + pembrolizumab) overview
MK-4280A is under development for the treatment of metastatic renal cell carcinoma (mRCC), melanoma, small-cell lung cancer, esophageal cancer, relapsed or refractory classical Hodgkin lymphoma, bladder cancer, metastatic urothelial carcinoma, cutaneous squamous cell carcinoma (cSCC) and endometrial cancer (EC) and metastatic colorectal cancer. It is administered intravenously and is a fixed dose combination of favezelimab and pembrolizumab. Favezelimab is an anti-LAG3 monoclonal antibody and pembrolizumab is an anti-PD-1 monoclonal antibody.
Merck overview
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
For a complete picture of (Favezelimab + pembrolizumab)’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Source link
#Favezelimab #pembrolizumab #Merck #Bladder #Cancer #Likelihood #Approval